Public Release: 

What factors affect non-compliance with endocrine therapy among young women with breast cancer?

Mary Ann Liebert, Inc./Genetic Engineering News

IMAGE

IMAGE: Journal of Adolescent and Young Adult Oncology (JAYAO) is a quarterly peer-reviewed journal dedicated to the promotion of interdisciplinary research, education, communication, and collaboration between health professionals in... view more

Credit: ©Mary Ann Liebert, Inc., publishers

New Rochelle, NY, February 16, 2016--A new study from Harvard Medical School of young women with hormone receptor-positive (HR+) breast cancer showed that more than half did not believe endocrine therapy was essential, even though it has been proven to reduce recurrence and improve survival. Young women with HR+ breast cancer are at increased risk for recurrence and decreased survival, yet they are also more likely to fail to adhere to endocrine treatment as prescribed, as reported in the study published in Journal of Adolescent and Young Adult Oncology (JAYAO), a multidisciplinary peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free to download on the JAYAO website until March 16, 2016.

The article "Perceptions, Attributions and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer" explores whether young women's views of endocrine therapy and the symptoms they attribute to the medication--whether tamoxifen or an aromatase inhibitor--affect their compliance with the prescribed treatment regimen.

Coauthors Hayley Walker, MD, Harvard Medical School, Boston, MA, Shoshana Rosenberg, ScD, MPH and Ann Partridge, Harvard Medical School and Dana-Farber Cancer Institute, Boston, Annette Stanton, PhD, University of California, Los Angeles, and Keith Petrie, PhD, The University of Auckland, New Zealand, emphasize the need for better education of young women with HR+ breast cancer about the benefits of endocrine therapy and the importance of medication adherence. They also highlight the more severe burden of menopausal symptoms young women may experience and the potential impact these side effects may have on non-adherence.

"This paper address an extremely important and previously unappreciated nuance to delivering care to the young adult breast cancer population," says Editor-in-Chief Leonard S. Sender, MD, University of California, Irvine and CHOC Children's Hospital, Orange, CA. "Now that this is known, interventions need to be implemented and then studied to assess whether they can change the current practice."

###

About the Journal

Journal of Adolescent and Young Adult Oncology (JAYAO) is a quarterly peer-reviewed journal dedicated to the promotion of interdisciplinary research, education, communication, and collaboration between health professionals in AYA oncology. JAYAO provides a forum for AYA cancer research and practice advances for all professional participants and researchers in care for AYA-aged cancer patients and survivors. The Journal's multidisciplinary editorial board and readership includes but is not limited to: pediatric, medical, and surgical oncologists of all types and specialties; oncology nurses and advanced practice staff; psychosocial and supportive care providers including psychiatrists, psychologists, and social workers; translational cancer researchers; and academic- and community-based pediatric and adult cancer institutions. Complete tables of content and a sample issue may be viewed on the Journal of Adolescent and Young Adult Oncology (JAYAO) website.

About the Society

The Society for Adolescent and Young Adult Oncology (SAYAO) is an international professional organization dedicated to improving adolescent and young adult cancer care through the promotion of interdisciplinary research, education, communication, and collaboration among health professionals. Patients and survivors aged 15-39 are a distinct patient population within oncology, and SAYAO focuses on the unique biological, clinical, psychosocial, and survivorship issues of this age group.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative medical and biomedical peer-reviewed journals, including Journal of Palliative Medicine and Cancer Biotherapy and Radiopharmaceuticals. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.